Apellis Pharmaceuticals reported its third quarter 2024 financial results, highlighting a U.S. net product revenue of $152 million for Syfovre. This figure falls short of the $168 million consensus estimate provided by Visible Alpha. The company is on track to file a supplemental New Drug Application (sNDA) for pegcetacoplan for C3G/primary IC-MPGN in early 2025. Additionally, Apellis Pharmaceuticals' stock dropped by 5.2% in pre-market trading following the announcement. Q3 sales were $152 million.